The Merck Group Website
The Merck Group Website

Innovating to help patients with unmet medical needs

What we do

We develop treatments for serious, life-altering conditions that currently have no cure.

We combine innovative biotechnology with established pharmaceutical science – a link that’s widely considered to offer tremendous potential. This complementary expertise in new chemical entities (NCEs) and new biological entities (NBEs) means we can generate leading-edge prescription drugs of either origin.

Integral to our R&D programs is developing patient-friendly drug delivery systems. Most biopharmaceuticals have to be injected under the skin. But by making these injections easier and less painful, we aim at enhancing patient adherence to therapy.

At the Medical Design Excellence Awards (MDEA) ceremony, easypod®, our first electromechanical growth hormone injection device, received a gold medal for its innovative design and ease of use. We’ve now launched easypod® in over 40 countries where it’s had a positive response from both patients and healthcare professionals.

Find out more about our therapeutic areas and leading brands:

Oncology – Erbitux®, UFT®

We develop therapies that specifically target cancer cells without damaging healthy cells. We focus on three therapeutic platforms: targeting the tumor cell, the tumor environment and the immune system. Our monoclonal antibody, Erbitux®, specifically blocks the epidermal growth factor receptor (EGFR) to enhance the effect of chemotherapy and radiotherapy.

Neurodegenerative diseases – Rebif®

We’re a market leader in the treatment of Multiple Sclerosis (MS) with Rebif®, approved for the treatment of relapsing-remitting MS in over 90 countries worldwide. And our research and development pipeline includes further potential treatments for neurodegenerative diseases including MS.

Fertility – GONAL-f®, Ovidrel, Luveris®, Cetrotide®, Crinone®, Pergoveris®

We’re the world leader in fertility treatment. We develop and market innovative products to help infertile couples at every stage of the reproductive cycle, from follicular development to early pregnancy. And our broad portfolio of gonadotropin hormones allows physicians to tailor treatment to individual patient needs.

Endocrinology – Saizen®, Serostim®, Kuvan®, Egrifta ®

We make recombinant human growth hormone available to treat growth hormone deficiency in children and adults (Saizen); and HIV-associated wasting (Serostim; only in US). With Kuvan® (sapropterin dihydrochloride), Merck Serono offers the only drug therapy in Europe indicated in the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) in patients over the age of four; or due to tetrahydrobiopterin BH 4 deficiency.

CardioMetabolic Care – Glucophage®, Concor®, Euthyrox®

We offer an extensive range of therapeutic options for the integrated management of cardiovascular and metabolic diseases. These include the Glucophage franchise of oral antidiabetics to treat type 2 diabetes, the beta-blocker bisoprolol (Concor®) and a complete range of thyroid hormones (Euthyrox®).



It takes a great many highly skilled people to transform medical science into tomorrow’s therapeutic solutions. You can help us make a difference in one of a host of diverse career opportunities at Merck Serono.


Job search
Please click here to search for available positions.


Merck´s Global Career Portal